News stories about Synlogic (NASDAQ:SYBX) have been trending somewhat positive recently, Accern Sentiment reports. The research firm scores the sentiment of press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Synlogic earned a coverage optimism score of 0.08 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 46.0977765770454 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Synlogic (SYBX) remained flat at $$10.45 on Monday. 9,000 shares of the company’s stock traded hands, compared to its average volume of 41,322. The company has a market cap of $170.18, a PE ratio of -1.11 and a beta of 3.17. Synlogic has a 12-month low of $8.76 and a 12-month high of $23.00.
Synlogic (NASDAQ:SYBX) last announced its quarterly earnings results on Monday, November 13th. The biotechnology company reported ($1.66) EPS for the quarter, missing the consensus estimate of ($0.50) by ($1.16). research analysts forecast that Synlogic will post -5.42 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Synlogic (NASDAQ:SYBX) Receives News Sentiment Rating of 0.08” was first posted by BBNS and is the sole property of of BBNS. If you are reading this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be viewed at https://baseballnewssource.com/markets/synlogic-sybx-given-daily-news-sentiment-rating-of-0-08/1818862.html.
Synlogic, Inc, formerly Mirna Therapeutics, Inc, is engaged in the development of a novel class of living treatments, Synthetic Biotic medicines. The Company uses its proprietary Synthetic Biotic development platform. Its pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU).
Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.